Literature DB >> 16275962

Progress in the prevention of pneumococcal infection.

James D Kellner1, Deirdre L Church, Judy MacDonald, Gregory J Tyrrell, David Scheifele.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16275962      PMCID： PMC1277039          DOI： 10.1503/cmaj.051150

Source DB:  PubMed          Journal:  CMAJ        ISSN： 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  3 in total

1.  Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP).

Authors: 
Journal:  MMWR Recomm Rep       Date:  1997-04-04

2.  Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease--United States, 1998-2003.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2005-09-16       Impact factor: 17.586

3.  Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine.

Authors:  Cynthia G Whitney; Monica M Farley; James Hadler; Lee H Harrison; Nancy M Bennett; Ruth Lynfield; Arthur Reingold; Paul R Cieslak; Tamara Pilishvili; Delois Jackson; Richard R Facklam; James H Jorgensen; Anne Schuchat
Journal:  N Engl J Med       Date:  2003-05-01       Impact factor: 91.245
  3 in total
  12 in total

1.  Immunization in Canada: a 6-year update.

Authors:  Scott A Halperin; Kiersten Pianosi
Journal:  J Can Chiropr Assoc       Date:  2010-06

2.  Conjugate vaccines and polysaccharide response.

Authors:  Sujoy Khan
Journal:  CMAJ       Date:  2006-03-28       Impact factor: 8.262

3.  Mortality reductions for older adults differ by race/ethnicity and gender since the introduction of adult and pediatric pneumococcal vaccines.

Authors:  Samir Soneji; Joshua Metlay
Journal:  Public Health Rep       Date:  2011 Mar-Apr       Impact factor: 2.792

4.  The burden of pneumococcal disease in the Canadian population before routine use of the seven-valent pneumococcal conjugate vaccine.

Authors:  Adrienne Morrow; Philippe De Wals; Geneviève Petit; Maryse Guay; Lonny James Erickson
Journal:  Can J Infect Dis Med Microbiol       Date:  2007-03       Impact factor: 2.471

5.  Streptococcus pneumoniae meningitis in Alberta pre- and postintroduction of the 7-valent pneumococcal conjugate vaccine.

Authors:  Jennie Johnstone; Gregory J Tyrrell; Thomas J Marrie; Sipi Garg; James D Kellner
Journal:  Can J Infect Dis Med Microbiol       Date:  2011       Impact factor: 2.471

6.  Pneumococcal conjugate vaccination in Canadian infants and children younger than five years of age: Recommendations and expected benefits.

Authors:  Carol A McClure; Michael W Ford; Jeff B Wilson; Jeff J Aramini
Journal:  Can J Infect Dis Med Microbiol       Date:  2006-01       Impact factor: 2.471

7.  Decline in pneumococcal meningitis after the introduction of the heptavalent-pneumococcal conjugate vaccine in northern France.

Authors:  F Dubos; I Marechal; M O Husson; C Courouble; M Aurel; A Martinot
Journal:  Arch Dis Child       Date:  2007-07-11       Impact factor: 3.791

8.  Presentation and management of pediatric orbital cellulitis.

Authors:  Sergio Fanella; Alex Singer; Joanne Embree
Journal:  Can J Infect Dis Med Microbiol       Date:  2011       Impact factor: 2.471

9.  Cost-effectiveness of 2 + 1 dosing of 13-valent and 10-valent pneumococcal conjugate vaccines in Canada.

Authors:  Stephanie R Earnshaw; Cheryl L McDade; Giovanni Zanotti; Raymond A Farkouh; David Strutton
Journal:  BMC Infect Dis       Date:  2012-04-24       Impact factor: 3.090

10.  Rationale for and protocol of a multi-national population-based bacteremia surveillance collaborative.

Authors:  Kevin B Laupland; Henrik C Schønheyder; Karina J Kennedy; Outi Lyytikäinen; Louis Valiquette; John Galbraith; Peter Collignon; Deirdre L Church; Daniel B Gregson; Pamela Kibsey
Journal:  BMC Res Notes       Date:  2009-07-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.